» Authors » Hajer Bin Shuraym

Hajer Bin Shuraym

Explore the profile of Hajer Bin Shuraym including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 5
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Alharthi R, Sueiro-Olivares M, Storer I, Bin Shuraym H, Scott J, Al-Shidhani R, et al.
Virulence . 2025 Jan; 16(1):2449075. PMID: 39825596
Sulfur metabolism is an essential aspect of fungal physiology and pathogenicity. Fungal sulfur metabolism comprises anabolic and catabolic routes that are not well conserved in mammals, therefore is considered a...
2.
van Rhijn N, Zhao C, Al-Furaiji N, Storer I, Valero C, Gago S, et al.
Nat Commun . 2024 Aug; 15(1):7126. PMID: 39164238
No abstract available.
3.
van Rhijn N, Zhao C, Al-Furaiji N, Storer I, Valero C, Gago S, et al.
Nat Commun . 2024 Jun; 15(1):4984. PMID: 38862481
More than 10 million people suffer from lung diseases caused by the pathogenic fungus Aspergillus fumigatus. Azole antifungals represent first-line therapeutics for most of these infections but resistance is rising,...
4.
van Rhijn N, Zhao C, Al-Furaji N, Storer I, Valero C, Gago S, et al.
Res Sq . 2023 Jul; PMID: 37398159
More than 10 million people suffer from lung diseases caused by the pathogenic fungus . The azole class of antifungals represent first line therapeutics for most of these infections however...
5.
van Rhijn N, Hemmings S, Storer I, Valero C, Bin Shuraym H, Goldman G, et al.
mBio . 2022 Oct; 13(6):e0221522. PMID: 36286521
Aspergillosis, in its various manifestations, is a major cause of morbidity and mortality. Very few classes of antifungal drugs have been approved for clinical use to treat these diseases and...